Preservation of endurance and mobility during allogeneic hematopoietic cell transplantation (alloHCT)

被引:0
|
作者
Limbach, M. [1 ,2 ]
Wehrle, A. [3 ]
机构
[1] Heidelberg Univ, NCT, Neuenheimer Feld 460, D-69120 Heidelberg, Germany
[2] Univ Freiburg, Klin Innere Med 1, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Univ Freiburg, Inst Bewegungs & Arbeitsmed, Hugstetter Str 55, D-79106 Freiburg, Germany
来源
关键词
allogeneic hematopoietic stem cell transplantation; endurance exercise; balance training; assessment methods;
D O I
10.1055/s-0042-103395
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
As a consequence of alloHCT, various side effects occur which lead to the decline of physical capability. The aim of this randomized pilot study (n = 13) was the preservation of the physical capability through endurance exercise or balance training and to investigate adaption to the new recommendations for assessment methods. Overall, there was a reduction of the physical capability despite therapeutic exercises. Whereas the assessment methods were well tolerated, the toxic therapy and the therapy-induced immobilization seemed to have altered normal cardiovascular und musculoskeletal training adaption and led to the weakness of aerobic capacity.
引用
收藏
页码:45 / 49
页数:5
相关论文
共 50 条
  • [1] Outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in anaplastic large cell lymphoma (ALCL)
    Hamadani, M.
    Chen, Y.
    Kharfan-Dabaja, M.
    Herrera, A.
    Sauter, C.
    Ahn, K.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 66 - 67
  • [2] Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
    Hu, Bei
    Lin, Xiao
    Lee, Hans C.
    Huang, Xuelin
    Tidwell, Rebecca S. Slack
    Ahn, Kwang Woo
    Hu, Zhen-Huan
    Jabbour, Elias
    Verstovsek, Srdan
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kharfan-Dabaja, Mohamed A.
    Hossain, Nasheed M.
    Marks, David I.
    Kamble, Rammuriti T.
    Inamoto, Yoshihiro
    Kindwall-Keller, Tamila
    Saad, Ayman
    Litzow, Mark R.
    Savani, Bipin N.
    Hale, Gregory A.
    Bacher, Ulrike
    Gerds, Aaron T.
    Liesveld, Jane L.
    Ustun, Celalettin
    Olsson, Richard F.
    Daly, Andrew
    Grunwald, Michael R.
    Solh, Melhem
    DeFilipp, Zachariah
    Aljurf, Mahmoud
    Wirk, Baldeep
    Akpek, Gorgun
    Nishihori, Taiga
    Cerny, Jan
    Seo, Sachiko
    Hsu, Jack W.
    Champlin, Richard
    de Lima, Marcos
    Alyea, Edwin
    Popat, Uday
    Sobecks, Ronald
    Scott, Bart L.
    Kantarjian, Hagop
    Cortes, Jorge
    Saber, Wael
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2811 - 2820
  • [3] Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
    Shah, Nirali
    Borowitz, Michael J.
    Robey, Nancy
    Gamper, Christopher
    Symons, Heather
    Loeb, David
    Wayne, Alan S.
    Chen, Allen
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S306 - S306
  • [4] Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)
    Bacher, Ulrike
    Klyuchnikov, Evgeny
    Carreras, Jeanette
    Le-Rademacher, Jennifer
    Laport, Ginna G.
    Montoto, Silvia
    Maloney, David G.
    Hari, Parameswaran
    BLOOD, 2011, 118 (21) : 234 - 234
  • [5] FACTORS PREDICTIVE OF RELAPSE OF HEMATOLOGIC MALIGNANCIES IN PEDIATRIC PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT)
    Shah, Nirali
    Borowitz, Michael
    Steinberg, Seth
    Robey, Nancy
    Gamper, Christopher
    Loeb, David
    Symons, Heather
    Wayne, Alan
    Chen, Allen
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S96 - S96
  • [6] Pre-Transplant Predictors of Cost of First Hospitalization for Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT)
    Broglie, Larisa
    Jin, Zhezhen
    Satwani, Prakash
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [7] The 10-years EBMT Landscape of Allogeneic Hematopoietic Cell Transplantation (Allohct) for Chronic Lymphocytic Leukemia
    Tournilhac, Olivier
    van Gelder, Michel
    Dreger, Peter
    Bornhaeuser, Martin
    Platzbecker, Uwe
    Scheid, Christof
    Beelen, Dietrich
    Jindra, Pavel
    Cornelissen, Jan J.
    Sengeloev, Henrik
    Nguyen, Stephanie
    Mayer, Jiri
    Stelljes, Matthias
    Dilhuydy, Marie-Sarah
    Griskevicius, Laimonas
    Vitek, Antonin
    Nikolousis, Manos
    Kroeger, Nicolaus
    Hellmann, Andrzej
    Santarone, Stella
    Zinger, Nienke
    Hayden, Patrick
    Yakoub-Agha, Ibrahim
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 60 - 60
  • [8] Conditional Survival and Mortality Risks after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients Who Survived Varying Length of Time after Allohct
    Wong, F. Lennie
    Xiao, Meisi
    Teh, Jennifer Berano
    Atencio, Liezl
    Gonzales, Alicia
    Hinton, Amy
    Iukuridze, David
    Forman, Stephen J.
    Nakamura, Ryotaro
    Armenian, Saro H.
    BLOOD, 2018, 132
  • [9] A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
    Davids, Matthew S.
    Kim, Haesook T.
    Costello, Caitlin L.
    Herrera, Alex F.
    Locke, Frederick L.
    Maegawa, Rodrigo O.
    Savell, Alexandra
    Mazzeo, Michael
    Avigan, David E.
    Chen, Yi-Bin
    Nikiforow, Sarah
    Ho, Vincent T.
    Cutler, Corey S.
    Alyea, Edwin P., III
    Bachireddy, Pavan
    Wu, Catherine J.
    Streicher, Howard
    Ball, Edward D.
    Bashey, Asad
    Soiffer, Robert J.
    Armand, Philippe
    BLOOD, 2018, 132
  • [10] Health Care Utilization Among Pediatric Patients Receiving Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
    Bourgeois, Wallace
    Jin, Zhezhen
    Huynh, Paul
    Bhatia, Monica
    George, Diane
    Satwani, Prakash
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S120 - S121